Please login to the form below

Not currently logged in
Email:
Password:

Abeona Therapeutics names CEO

Carsten Thiel joins the biopharma from Alexion

Rare genetic disease focused biopharma Abeona Therapeutics has named its chief executive officer in the form of Carsten Thiel.

Formerly serving as Alexion Pharmaceutical’s executive vice president and chief commercial officer, Thiel brings experience in leading commercial operations to his new position.

Steven Rouhandeh, executive chairman of Abeona, said: “As CEO, Carsten Thiel brings a unique combination of extensive experience in research and global rare disease commercialisation to Abeona.

“In his recent positions, he successfully created value by building cohesive talented teams, driving the commercial success of multiple products globally and fostering entrepreneurial culture; all key aspects that will be critical to our success in these areas in the years ahead.”

Following a 25-year career in the biopharmaceutical industry, Thiel has held numerous roles for several biopharma’s including Amgen and Roche.

20th April 2018

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
nzyme

The nzyme group focuses on the three fundamentals that enable full patient access - Education, Access & Activation. Our specialist...

Latest intelligence

Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....
Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...